Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Azitra Inc ( (AZTR) ) has provided an update.
On October 1, 2025, Azitra, Inc. received a notice from NYSE American LLC regarding non-compliance with the minimum stockholders’ equity requirement, having only $2.2 million against the required $4 million. Azitra has until October 31, 2025, to submit a compliance plan to avoid delisting, with a deadline for achieving compliance by April 1, 2027. The notice does not immediately affect the company’s stock trading or operations.
The most recent analyst rating on (AZTR) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.
Spark’s Take on AZTR Stock
According to Spark, TipRanks’ AI Analyst, AZTR is a Neutral.
Azitra Inc’s overall stock score is primarily driven by weak financial performance and unfavorable technical indicators. While corporate events reflect positive strategic developments, they are insufficient to offset significant financial concerns and poor valuation metrics.
To see Spark’s full report on AZTR stock, click here.
More about Azitra Inc
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. Its lead program, ATR-12, targets Netherton syndrome, a rare skin disease, while ATR-04 addresses EGFR inhibitor-associated rash. The company leverages a proprietary platform of engineered proteins and a microbial library, enhanced by AI and machine learning, to develop its products.
Average Trading Volume: 2,634,560
Technical Sentiment Signal: Sell
Current Market Cap: $3.9M
For detailed information about AZTR stock, go to TipRanks’ Stock Analysis page.